GSK inks $231M manufacturing deal as Hal Barron anticipates fruitful year for pruned R&D group

Almost halfway into the big turnaround year that Hal Barron has blueprinted for GlaxoSmithKline’s R&D team, the Big Pharma is unveiling a $231 million manufacturing deal to match the growing commercial portfolio.